Combo Treatment Doubles Survival for Patients With Advanced Kidney Cancer
TUESDAY, Sept. 17, 2024 (HealthDay News) — A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer. Researchers at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., developed the new regimen, a combination of pazopanib (Votrient) and bevacizumab (Avastin). Pazopanib is fromContinue Reading